TOS.TO - TSO3 Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.90
-0.04 (-4.26%)
At close: 3:20PM EDT
Stock chart is not supported by your current browser
Previous Close0.94
Open0.95
Bid0.90 x 0
Ask0.92 x 0
Day's Range0.88 - 0.96
52 Week Range0.56 - 3.30
Volume137,230
Avg. Volume227,338
Market Cap83.602M
Beta2.72
PE Ratio (TTM)N/A
EPS (TTM)-0.08
Earnings DateMay 8, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.22
  • CNW Group16 days ago

    TSO3 Announces the Vote Results from its Annual Meeting of the Shareholders and the Appointment New Chairperson

    QUEBEC CITY and MYRTLE BEACH, SC, May 10 2018 /CNW Telbec/ - TSO 3 Inc. (TSX: TOS), ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices in healthcare ...

  • CNW Group17 days ago

    IIROC Trade Resumption - TOS

    TORONTO , May 9, 2018 /CNW/ - Trading resumes in: Company: TSO3 Inc. TSX Symbol: TOS (all issues) Resumption (ET): 13:45 IIROC can make a decision to impose a temporary suspension (halt) of trading in ...

  • CNW Group17 days ago

    TSO3 Obtains New Clearance for the STERIZONE® VP4 Sterilizer

    "In 2009, TSO3 set itself on a path to bring about lasting and meaningful change to healthcare sterilization practices. The recent and highly publicized outbreaks associated with use of flexible endoscopes have highlighted the need for innovative approaches to reprocessing of these complex devices.

  • CNW Group17 days ago

    IIROC Trading Halt - TOS

    TORONTO , May 9, 2018 /CNW/ - The following issues have been halted by IIROC: Company: TSO3 Inc. TSX Symbol: TOS (all issues) Reason: Pending News Halt Time (ET): 12:15 PM IIROC can make a decision to ...

  • CNW Group18 days ago

    TSO3 Reports First Quarter 2018 Results

    QUEBEC CITY and MYRTLE BEACH, SC , May 8, 2018 /CNW Telbec/ - TSO 3 Inc. (TSX: TOS) ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices in healthcare ...

  • ACCESSWIRE24 days ago

    Today’s Research Reports on Fennec Pharmaceuticals, Aptose Biosciences, TSO3 and ImmunoVaccine

    NEW YORK, NY / ACCESSWIRE / May 2, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • CNW Group26 days ago

    TSO3 to Report First Quarter 2018 Results and Hold Annual Meeting of Shareholders on Wednesday, May 9, 2018

    QUEBEC CITY and MYRTLE BEACH, SC, April 30 2018 /CNW Telbec/ - TSO3 Inc. (TSX:TOS.TO - News), ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, will hold a conference call on Wednesday, May 9, 2018 to discuss its financial results for the first quarter ended March 31, 2018 and will then hold its Annual Meeting of Shareholders. Financial results will be issued in a press release prior to the call.

  • CNW Grouplast month

    TSO3 's Chief Science Officer to moderate Educational Panel at the IAHCSMM Annual Congress

    QUEBEC CITY and MYRTLE BEACH, SC , April 26, 2018 /CNW Telbec/ - TSO 3 Inc. (TSX: TOS), ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices in ...

  • Baystreetlast month

    Stocks in play: TSO3 Inc.

    Announced that an independent laboratory has completed studies demonstrating the efficacy of the STERIZONE® ...

  • CNW Grouplast month

    TSO3 Details Results of Prion Inactivation Studies

    Prions generated great public concern after an outbreak of bovine spongiform encephalopathy occurred in many European countries and scientific evidence indicated its transmission to humans.  Prions are unique in demonstrating a high level of resistance to conventional device reprocessing methods and have been linked to patient-to-patient transmission via contaminated medical devices. "This study reinforces the broader clinical applications of our sterilization technology", stated R.M. (Ric) Rumble TSO3's President and CEO. "Results obtained by the independent laboratory confirmed the efficacy and performance of the STERIZONE® VP4 Sterilizer for prion inactivation.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Acerus Pharmaceuticals, TSO3, BELLUS Health and ImmunoVaccine

    NEW YORK, NY / ACCESSWIRE / April 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Group2 months ago

    TSO3 Appoints Dr. Douglas Dieter to its Board of Directors

    QUEBEC CITY and MYRTLE BEACH, SC, April 2, 2018 /CNW Telbec/ - TSO3 Inc. (TSX:TOS.TO - News), ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, today announced that it has appointed Dr. Doug Dieter to its board of directors. Dr. Dieter is currently a Managing Director at Ares Management, an asset manager headquartered in Los Angeles, CA, where he is responsible for investments across the healthcare spectrum, including inpatient and outpatient healthcare services, health insurers, medical device and pharmaceutical and biotech companies.

  • CNW Group2 months ago

    TSO3 Reports Fourth Quarter and Full Year 2017 Results

    QUEBEC CITY and MYRTLE BEACH, SC , March 20, 2018 /CNW Telbec/ - TSO 3 Inc. (TSX: TOS) ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices in healthcare ...

  • PR Newswire2 months ago

    TSO3 Reports Fourth Quarter and Full Year 2017 Results

    QUEBEC CITY and MYRTLE BEACH, SC , March 20, 2018 /PRNewswire/ - TSO 3 Inc. (TSX: TOS) ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices in healthcare ...

  • PR Newswire2 months ago

    TSO3 Submits Response to US Regulators in Support of Terminal Sterilization of Duodenoscopes

    QUEBEC CITY and MYRTLE BEACH, SC, March 19, 2018 /PRNewswire/ - TSO3 Inc. (TOS.TO), ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, today announced that it has provided its final Additional Information (AI) response to US Regulators in support of extending the claims of the Company's STERIZONE® VP4 Sterilizer to include the terminal sterilization of duodenoscopes. In the AI response, the Company included data on modified leak test experiments, testing to confirm lack of fluid ingress occurring under the distal end cap of the devices, as well as real-world data from market research commissioned by TSO3 reflecting the actual use-life of duodenoscopes. "The Company believes that its response is consistent with 510(k) requirements demonstrating the same intended use and the same technological characteristics as the predicate device, which is the existing cleared TSO3 STERIZONE® VP4 Sterilizer" stated R.M. (Ric) Rumble, TSO3's President and CEO.

  • CNW Group2 months ago

    TSO3 Submits Response to US Regulators in Support of Terminal Sterilization of Duodenoscopes

    QUEBEC CITY and MYRTLE BEACH, SC, March 19, 2018 /CNW Telbec/ - TSO3 Inc. (TSX:TOS.TO - News), ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, today announced that it has provided its final Additional Information (AI) response to US Regulators in support of extending the claims of the Company's STERIZONE® VP4 Sterilizer to include the terminal sterilization of duodenoscopes. In the AI response, the Company included data on modified leak test experiments, testing to confirm lack of fluid ingress occurring under the distal end cap of the devices, as well as real-world data from market research commissioned by TSO3 reflecting the actual use-life of duodenoscopes. "The Company believes that its response is consistent with 510(k) requirements demonstrating the same intended use and the same technological characteristics as the predicate device, which is the existing cleared TSO3 STERIZONE® VP4 Sterilizer" stated R.M. (Ric) Rumble, TSO3's President and CEO.

  • PR Newswire2 months ago

    TSO3's STERIZONE® VP4 Sterilizer Receives 510(k) Clearance for a Significant Enhancement

    All of the Company's new STERIZONE® VP4 Sterilizers, along with any upgraded units in existing inventories, can now incorporate this new feature and several other additional customer improvements intended to improve the user experience. The STERIZONE® VP4 Sterilizer is a low-temperature sterilization system that utilizes the dual-sterilants of vaporized hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilization of heat and moisture sensitive medical devices.

  • CNW Group2 months ago

    TSO3's STERIZONE® VP4 Sterilizer Receives 510(k) Clearance for a Significant Enhancement

    All of the Company's new STERIZONE® VP4 Sterilizers, along with any upgraded units in existing inventories, can now incorporate this new feature and several other additional customer improvements intended to improve the user experience. The STERIZONE® VP4 Sterilizer is a low-temperature sterilization system that utilizes the dual-sterilants of vaporized hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilization of heat and moisture sensitive medical devices.

  • PR Newswire3 months ago

    TSO3 Sets Fourth Quarter and Full Year 2017 Earnings Call for Wednesday, March 21, 2018 at 8:30 a.m. EDT

    QUEBEC CITY and MYRTLE BEACH, SC , March 7, 2018 /PRNewswire/ - TSO 3 Inc. (TSX: TOS) ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices in healthcare ...

  • CNW Group3 months ago

    TSO3 Sets Fourth Quarter and Full Year 2017 Earnings Call for Wednesday, March 21, 2018 at 8:30 a.m. EDT

    QUEBEC CITY and MYRTLE BEACH, SC , March 7, 2018 /CNW Telbec/ - TSO 3 Inc. (TSX: TOS) ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices in healthcare ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Canopy Growth, Fennec Pharmaceuticals, Neptune Technologies & Bioressources and TSO3

    NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Group3 months ago

    TSO3 to Present at the RBC Capital Markets Healthcare Conference

    QUEBEC CITY and MYRTLE BEACH, SC, Feb. 14, 2018 /CNW Telbec/ - TSO3 Inc. (TSX:TOS.TO - News), ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, today announced the Company will participate in the RBC Capital Markets Healthcare Conference in New York, New York. TSO3's management is scheduled to present on Thursday, February 22, 2018 at 1:35 PM EST. An audio webcast of the Company's presentation will be available in the investor relations section of TSO3's website at www.tso3.com.

  • PR Newswire3 months ago

    TSO3 to Present at the RBC Capital Markets Healthcare Conference

    QUEBEC CITY and MYRTLE BEACH, SC, Feb. 14, 2018 /PRNewswire/ - TSO3 Inc. (TOS.TO), ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, today announced the Company will participate in the RBC Capital Markets Healthcare Conference in New York, New York. TSO3's management is scheduled to present on Thursday, February 22, 2018 at 1:35 PM EST. An audio webcast of the Company's presentation will be available in the investor relations section of TSO3's website at www.tso3.com.

  • PR Newswire4 months ago

    IIROC Trade Resumption - TOS

    TORONTO , Jan. 25, 2018 /CNW/ - Trading resumes in: Company: TSO3 Inc. TSX Symbol: TOS (all issues) Resumption (ET): 10:45 AM IIROC can make a decision to impose a temporary suspension (halt) of trading ...

  • CNW Group4 months ago

    IIROC Trade Resumption - TOS

    TORONTO , Jan. 25, 2018 /CNW/ - Trading resumes in: Company: TSO3 Inc. TSX Symbol: TOS (all issues) Resumption (ET): 10:45 AM IIROC can make a decision to impose a temporary suspension (halt) of trading ...